Prostate cancer is one of the major health threatening cancers in men. At present, the usual clinical treatments of prostate cancer include surgery, radio and chemotherapy. The main chemotherapeutics agents includes steroidal and nonsteroidal anti-androgen drugs. However, the drugs become ineffective after a long-term use due to variation of androgen receptors. Hence, it is important to search for new and better drugs against prostate cancer. According to many studies, aberrant expression of the enzymes like 15-lipoxygenase 1 (15-LOX-1) that convert unsaturated fatty acids arachidonic acid (AA) and linoleic acid (LA) to bioactive lipid metabolites, appears to significantly contribute to the development of prostate cancer. So inhibition of 15-LOX-1 may result to induction of apoptosis. Considering the observed cytotoxic effects of two synthetic 15-LOX-1 inhibitors, 6-Farnesyloxycoumarin (6F) and 4-Farnesyloxycoumarin (4F), synergistic effects of these compounds were studied by MTT assay on a prostate cancer cell line (PC-3) in comparison with HFF3 cells as control. 4F had the same cytotoxic potency (IC50: 33.38 µg/ml) on both cell lines. Based on the observed cytotoxic potency of the mentioned compounds, several mixture of 6F (12.5 µg/ml) with different concentrations of 4F (3, 6.25, 12.5, 25 and 50 µg/ml) were used to evaluate the synergistic effects in 24, 48 and 72 hours. results showed that the combination protocol leads to modification of 4F IC50 from 33.38 to 22.62 µg/ml, while no synergistic effects of the combined agents were observed on HFF3 cells.

Keywords